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Abstract
The terrain is well explored regarding genes whose gene expression is up-regulated upon binding
of thyroid hormone (TH) to its nuclear receptor. This regulation mechanism has been intensively
studied and is well understood. In contrast, a lot of white spots remain on the map when it comes
to target genes whose expression is down-regulated upon binding of TH to the thyroid hormone
receptor (TR). Since no consistent mechanism has been proposed to explain ligand-dependent
down-regulation of target gene transcription several working hypotheses favour different
molecular mechanisms. Some working theories suggest a direct binding of TR to regulatory
elements of target genes. Others favour models that are independent of a direct DNA binding
event. However recent data suggested that a direct binding of TR to DNA is dispensable for TH-
dependent negative gene transcription.
Introduction
Regulation of gene expression in response to TH
a) Up-regulation by TH – the easy story
Thyroid hormone regulates gene expression in a positive
and negative manner. The mechanism of positively TH-
regulated gene transcription has been intensively studied
and is well understood. The thyroid hormone receptor
(TR) binds to thyroid hormone response elements (TREs)
which are located within regulatory elements of TH target
genes. If the ligand (i.e. triiodothyronine; T3) is present,
liganded TR recruits a huge coactivator complex. This
coactivator complex possesses or recruits several enzy-
matic activities which modify the chromatin of target
genes generating an open structure allowing for transcrip-
tion. If the ligand is absent the un-liganded TR undergoes
a conformational change which releases the coactivator
complex and recruits a corepressor complex. Again this
corepressor complex integrates several enzymatic activi-
ties modifying chromatin toward a closed and transcrip-
tional silent state. These processes are well documented
and discussed in comprehensive and excellent review arti-
cles elsewhere; see e.g. [1-3].
b) Down-regulation by TH – the complicate story
Besides positively TH-regulated target genes there are
clearly those genes whose gene expression is negatively
regulated upon administration of TH. The probably best
known example is the down-regulation of thyrotropin
(TSH) in the pituitary as part of the negative endocrine
hypothalamus-pituitary-thyroid feedback loop. However
also in other tissues (e.g. the liver) negative gene regula-
tion is a well known regulation pattern in microarray
analysis [4-8]. The portion of negatively regulated genes
varies greatly between 20 to >50% in different studies
depending on the experimental design (e.g. the procedure
to induce hypothyroidism in the animals or the duration,
concentration and nature of TH treatment). From a mech-
anistically point of view, it should be noted that the
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down-regulation phenomenon is preserved in transient
transfection experiments in cell culture, thus other in vivo
relevant aspects of TH metabolism such as local TH avail-
ability controlled by membrane transporters or local acti-
vation/inactivation by deiodinases could be ignored in
this experimental setting. Since positive and negative reg-
ulation takes place within the same cell system the diver-
gent regulation mechanisms can be ascribed to the nature
of different DNA response elements. The question
remains how this negative regulation might occur. In
principle there are three major working hypotheses trying
to explain negative TH-mediated gene transcription. One
of them (model A) suggests a direct binding of TR to DNA,
whereas models B and C favour mechanisms without a
direct TR-DNA binding (Figure 1).
(A) TR binds to specific negative thyroid hormone
response elements (negative TREs). Due to the specific
composition of these DNA response elements the TR
undergoes specific conformational changes leading to a
recruitment of a coactivator complex in the absence of TH.
In contrast, binding of the ligand recruits a corepressor
complex to the liganded TR. Of note, the functional read-
out is diametrically opposed compared to the readout for
positively regulated genes (see above).
(B) A second model suggests that TR does not bind to
DNA directly but rather to another transcription factor via
protein-protein interactions. Again, the un-liganded TR
(bound to DNA via transcription factor X) recruits a coac-
tivator complex whereas the liganded TR recruits a core-
pressor complex.
(C) Finally, a third model suggests that a soluble, not
DNA-bound TR sequesters cofactors away from other
DNA-bound transcription factor-cofactor complexes.
Sequestering of corepressor components from DNA-
bound transcription factors finally leads to an activation
Alternative models for negative gene transcription by thyroid hormone Figure 1
Alternative models for negative gene transcription by thyroid hormone. A) Thyroid hormone receptor (TR) binds 
together with its dimerization partner RXR to a negative thyroid hormone response element (negative TRE). The un-liganded 
TR recruits a coactivator complex (CoA) leading to gene activation. If thyroid hormone (TH) binds to TR the liganded TR 
recruits a corepressor complex (CoR) leading to silencing of gene expression. B) TR does not bind directly to DNA but rather 
via unknown transcription factors (TF X). The functional readout is as described for model A. C) TR does not bind to DNA at 
all but sequesters CoR away from DNA-bound transcription factors (TF X) in the absence of TH. In the presence of TH, lig-
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of gene expression whereas sequestering of coactivators
leads to a repression of gene transcription.
Pros and cons of the three suggested models
Several pros and cons exist for all of the three models and
no uniform model is in sight which takes in account all
aspects of negative gene regulation.
Model A
Several reports described negative TREs (Figure 1, model
A) on the basis of classical reporter gene assays in cell cul-
ture. DNA sequences close to the transcriptional start site
(the so-called z-boxes) have been suggested to serve as
negative TREs [9-17]. However; consecutive 5' deletion of
promoter sequences to the transcriptional start site or
introducing of point mutations at this site dampened the
reporter gene activity close to background activities. Thus
a potential down-regulation effect (which is probably still
present) might simply be lost in the background noise of
the remaining promoter activity. Furthermore, introduc-
ing of a z-box into a heterologous promoter context could
not preserve a down-regulation effect (an assay which is
routinely used for positive TREs). Moreover, a direct bind-
ing of TR could not be detected in mammalian one-hybrid
cell experiments using a chimeric fusion protein of TR
with the viral activator domain VP16 which activates gene
transcription TH-independently [12,18,19]. Finally, a
high-affinity binding of TR to a negative TRE has not been
identified in biochemical assays using in vitro translated
or bacterially expressed TR. Compared to classical positive
TREs the binding affinities of negative TREs are at least
two orders of magnitudes lower [9,12,14,15,17].
One major support for the model of negative TREs came
from experiments by Frederic Wondisford and colleagues.
They investigated the double mutant E125G; G126S
within TRβ (so-called GS mutant) which conserved the
overall zinc finger structure of the DNA binding domain
(DBD) but altered the DNA binding specificity [20]. The
GS mutant did not bind to a classical DR+4 TRE but rather
to a mixed thyroid hormone/glucocorticoid hormone
response element. However, the GS mutant still activates
some major TH target genes which contain a mixed thy-
roid/glucocorticoid hormone response element (DR+4+2
element) [21,22] (unpublished data). This might be con-
nected to the phenotype of GS mutant knock-in mice
which show some but not all phenotypical alterations
compared to classical TRβ knock-out mice [23]. Recent
data from our laboratory indicated that targeting of full-
length TR to DNA via a heterologous Gal4-DBD leads to
an activation of gene expression in response to TH [19].
This finding is consistent with data using a similar experi-
mental system in transgenic mice [24].
Model B
If TR did not bind directly to DNA it might bind via pro-
tein-protein interactions to a transcription factor as a
bridging factor in order to target TR to specific regulatory
elements (Figure 1, model B). Several recent publications
support this idea opening the avenue for cell type specific
regulation. One example might be the interaction of TR
with the pituitary-specific transcription factors GATA2
and Pit1, which are important regulators of TSH transcrip-
tion [25,26]. TR has been shown to physically interact
with GATA2 and this is ensured via the DBD of TR [26].
Another interesting connection might be the antagonism
of the cAMP pathway with the TH pathway which is
accomplished by physical interaction between CREB and
TR which – again – is mediated via the DBD of TR [13,27].
In addition TR-DBD might have several non-genomic
effects, e.g. antagonising β-catenin activation via increased
proteasomal degradation [28]. Many other examples of
TR-DBD interactions with other transcription factors or
chromatin components have been described and – inter-
estingly – some of these protein-protein contacts appear
to be ligand-dependent. Only in the presence of thyroid
hormone TR and HDAC2 are recruited to the TSHβ pro-
moter and a biochemical fine mapping identified the TR-
DBD as binding domain for HDAC [9]. A ligand-depend-
ent recruitment of HDAC would help to explain silencing
of target gene transcription in response to TH. Other
examples are the MED1/TRAP220 nucleosome remodel-
ling complex and the insulator protein CTCF. The MED1/
TRAP220 complex re-positioned nucleosomes on the
Crabp1 gene in a TH-dependent manner which leads to
an altered access of the basal transcription machinery and
consequently to altered transcription rates. However, the
role of TR within this process is not clear and both gene
activation and gene repression in response to TH has been
reported [29,30]. The insulator protein CTCF dampens
gene transcription in an enhancer blocking assay only if
liganded-TR is bound to an adjacent TRE. If the ligand is
absent the enhancer activity could not be blocked by
CTCF [31]. With other words, gene transcription rates are
high in the absence of TH and low in the presence of TH
– the typical readout of a negatively regulated gene. All
these data suggested a role for TR and TH in negative gene
transcription; however, it remains to be elucidated
whether the DBD of TR is responsible for direct DNA
binding and/or protein-protein interaction. Unfortu-
nately, currently widely used chromatin immunoprecipi-
tation assays could not distinguish between those factors
which are directly bound to DNA and those factors which
are indirectly bound to DNA as part of the chromatin
complex. However, a modification of local chromatin
structure has to be kept in mind to understand these proc-
esses.Thyroid Research 2008, 1:4 http://www.thyroidresearchjournal.com/content/1/1/4
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Model C
Following an alternative hypothesis TR might not bind to
DNA at all (neither directly (model A) nor indirectly
(model B)), but rather sequesters cofactors from DNA-
bound transcription factor-cofactor complexes (Figure 1,
model C). Such a scenario has been demonstrated for
corepressor NCoR and coactivator SRC-1 which are
directed to DNA via a heterologous Gal4-DBD. In this
experimental setting TR represses gene transcription of a
reporter gene in response to TH without directly binding
to DNA [18,19]. Soluble, non-DNA-bound TR might
compete for limiting amount of cofactors, e.g. for SRC-1,
a major coactivator for TR. In line with this argumentation
SRC-1 knock-out mice show features of thyroid hormone
resistance including several defects to properly regulate
gene expression in response to TH [32]. Furthermore, TRβ
E457A knock-in mice harbouring a defective coactivator
binding site demonstrated alterations in positively and –
paradoxically – negatively regulated TH target genes [33].
On the other hand the corepressor NCoR appears to be
also essential for down-regulation since knock-down pre-
vents negative gene regulation whereas re-introducing of
NCoR reconstitutes this activity [14,34]. It remains
unclear whether TR is part of the local chromatin complex
or whether or not TR is directly or indirectly bound to
DNA. If TR did not bind directly to target DNA (model B)
the problem to specifically regulate only a subset of target
genes arises. One could speculate that a yet to defined sub-
set or combination of transcription factors or cofactors
might be critical for regulating these target genes. How-
ever, the specificity problem emerges even more if we pos-
tulate a non-DNA bound TR (model C).
Further perspectives
Up to now no convincing data have been presented
doubtlessly supporting one particular model by discard-
ing hitherto alternative models. Taking together recent
data a direct binding of TR to negative TREs (model A)
appears to be unlikely due to the lack of high-affinity
binding sites for TR. Rather TR is involved in modulating
the transcriptional activity of other transcription factors
either directly (model B) or indirectly (model C). Clearly
the DBD of TR participates in these processes independent
of its function to bind DNA. Furthermore, cell-type and/
or context-specific post-translational modifications might
additionally contribute. Identification of TR binding sites
by chromatin immunoprecipitation and correlation with
adjacent DNA sequences (as successfully performed for
the estrogen receptor [35]) are eagerly awaited to substan-
tiate models for negative gene regulation by thyroid hor-
mone.
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